WARFARIN: PLACE IN THE ANTICOAGULANT THERAPY TODAY

Abstract

A trial fibrillation is the most common cardiac source of systemic emboli and car-a significant reduction or even blockage of dioembolic stroke. Anticoagulants are recommended for preventing stroke in patients with non-valvular atrial fibrillation. Warfarin reduces the risk of stroke in patients with AF by approximately two-thirds. New oral anticoagulants are becoming more common in recent years. Despite this, a number of clinical situations remain where the only possible anticoagulant is warfarin.

Keywords

• фибрилляция предсердий
• варфарин
• дабигатран
• ривароксабан
• апиксабан
• шкала same-tt2r2